Drug intelligence / Profile preview

HE-MD11

Development stage: Preclinical
Lead developer: Longhorn Vaccines and Diagnostics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

HE-MD11 is a monoclonal antibody (IgG) developed by Longhorn Vaccines and Diagnostics that targets bacterial peptidoglycan (PGN). Peptidoglycan is a structural component of bacterial cell walls that can leak into the systemic circulation (metabolic endotoxemia) or cross the blood-brain barrier, contributing to chronic inflammation and 'inflammaging'. By binding to PGN and PGN-containing components, HE-MD11 is designed to neutralize these pro-inflammatory molecules and facilitate their immune clearance via opsonization. The drug is being developed for the treatment of metabolic diseases and neuroinflammatory diseases, where PGN-driven inflammation is thought to play a significant role in disease progression.

Other names: anti-PGN IgG

Targets

PGN (Peptidoglycan)

Beyond the preview

Go deeper on HE-MD11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HE-MD11.

Explore the full profile